Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Pittsburgh
Bayer
Hummingbird Bioscience
Boehringer Ingelheim
Novartis
Astellas Pharma Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Medical Center Groningen
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
AVEO Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Pfizer
Pfizer
Seagen Inc.
Fate Therapeutics
Tianjin Medical University Cancer Institute and Hospital
Alterome Therapeutics, Inc.
Verastem, Inc.
NRG Oncology
H. Lee Moffitt Cancer Center and Research Institute
Novartis
M.D. Anderson Cancer Center
Revolution Medicines, Inc.
National Cancer Institute (NCI)
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
University of Chicago
Revolution Medicines, Inc.
Pfizer
Erasca, Inc.
Erasca, Inc.
Fudan University
Eastern Cooperative Oncology Group
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Gustave Roussy, Cancer Campus, Grand Paris